Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

Cited In for PubMed (Select 16409293)

1.

Eosinophilia in mast cell disease.

Kovalszki A, Weller PF.

Immunol Allergy Clin North Am. 2014 May;34(2):357-64. doi: 10.1016/j.iac.2014.01.013. Epub 2014 Mar 13. Review.

2.
3.

Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.

Yamada Y, Rothenberg ME, Cancelas JA.

Transl Oncogenomics. 2006 Dec 5;1:53-63. Print 2006.

4.

Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Haenisch B, Nöthen MM, Molderings GJ.

Immunology. 2012 Nov;137(3):197-205. doi: 10.1111/j.1365-2567.2012.03627.x. Review.

5.

Eosinophilic myeloproliferative disorders.

Klion AD.

Hematology Am Soc Hematol Educ Program. 2011;2011:257-63. doi: 10.1182/asheducation-2011.1.257. Review.

6.

Markers of tyrosine kinase activity in eosinophilic esophagitis: a pilot study of the FIP1L1-PDGFRα fusion gene, pERK 1/2, and pSTAT5.

Dellon ES, Bower JJ, Keku TO, Chen X, Miller CR, Woosley JT, Orlando RC, Shaheen NJ.

Dis Esophagus. 2012 Feb;25(2):166-74. doi: 10.1111/j.1442-2050.2011.01230.x. Epub 2011 Aug 5.

7.

FIP1L1/PDGFR alpha-associated systemic mastocytosis.

Yamada Y, Cancelas JA.

Int Arch Allergy Immunol. 2010;152 Suppl 1:101-5. doi: 10.1159/000312134. Epub 2010 Jun 4. Review.

8.

T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.

Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, Majewski M, Kyrcz-Krzemien S.

Haematologica. 2009 Sep;94(9):1236-41. doi: 10.3324/haematol.2008.005447.

9.

Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Tefferi A.

J Cell Mol Med. 2009 Feb;13(2):215-37. doi: 10.1111/j.1582-4934.2008.00559.x. Epub 2008 Oct 23. Review.

10.

FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, Satoh Y, Shibayama H, Tanaka H, Iwama A, Kanakura Y.

J Biol Chem. 2009 Mar 20;284(12):7719-32. doi: 10.1074/jbc.M807489200. Epub 2009 Jan 14.

11.

Hypereosinophilic syndromes.

Roufosse FE, Goldman M, Cogan E.

Orphanet J Rare Dis. 2007 Sep 11;2:37. Review.

12.

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S, Noel P, Law MA, Hartsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB.

Blood. 2007 Nov 15;110(10):3552-6. Epub 2007 Aug 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk